1
|
Abstract
INTRODUCTION Kinins are peptide mediators exerting their pro-inflammatory actions by the selective stimulation of two distinct G-protein coupled receptors, termed BKB1R and BKB2R. While BKB2R is constitutively expressed in a multitude of tissues, BKB1R is hardly expressed at baseline but highly inducible by inflammatory mediators. In particular, BKB1R was shown to be involved in the pathogenesis of numerous inflammatory diseases. Areas covered: This review intends to evaluate the therapeutic potential of substances interacting with the BKB1R. To this purpose we summarize the published literature on animal studies with antagonists and knockout mice for this receptor. Expert Opinion: In most cases the pharmacological inhibition of BKB1R or its genetic deletion was beneficial for the outcome of the disease in animal models. Therefore, several companies have developed BKB1R antagonists and tested them in phase I and II clinical trials. However, none of the developed BKB1R antagonists was further developed for clinical use. We discuss possible reasons for this failure of translation of preclinical findings on BKB1R antagonists into the clinic.
Collapse
Affiliation(s)
- Fatimunnisa Qadri
- a Max-Delbrück Center for Molecular Medicine (MDC) , Berlin , Germany
| | - Michael Bader
- a Max-Delbrück Center for Molecular Medicine (MDC) , Berlin , Germany.,b Berlin Institute of Health (BIH) , Berlin , Germany.,c Charité University Medicine Berlin , Germany.,d German Center for Cardiovascular Research (DZHK) site Berlin , Berlin , Germany.,e Institute for Biology , University of Lübeck , Lübeck , Germany
| |
Collapse
|
2
|
Lupala CS, Gomez-Gutierrez P, Perez JJ. New insights into the stereochemical requirements of the bradykinin B1 receptor antagonists binding. J Mol Graph Model 2016; 68:184-196. [PMID: 27469392 DOI: 10.1016/j.jmgm.2016.06.010] [Citation(s) in RCA: 12] [Impact Index Per Article: 1.5] [Reference Citation Analysis] [Abstract] [Key Words] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/28/2015] [Revised: 06/17/2016] [Accepted: 06/17/2016] [Indexed: 02/01/2023]
Abstract
Bradykinin (BK) is a nonapeptide involved in several pathophysiological conditions including among others, septic and haemorrhagic shock, anaphylaxis, arthritis, rhinitis, asthma, inflammatory bowel disease. Accordingly, BK antagonists have long been sought after for therapeutic intervention. Action of BK is mediated through two different G-protein coupled receptors known as B1 and B2. Although there are several B1 antagonists reported in literature, their pharmacological profile is not yet optimal so that new molecules need to be discovered. In the present work we have constructed an atomistic model of the B1 receptor and docked diverse available non-peptide antagonists in order to get a deeper insight into the structure-activity relationships involving binding to this receptor. The model was constructed by homology modeling using the chemokine CXC4 and bovine rhodopsin receptors as template. The model was further refined using molecular dynamics for 600ns with the protein embedded in a POPC bilayer. From the refinement process we obtained an average structure that was used for docking studies using the Glide software. Antagonists selected for the docking studies include Compound 11, Compound 12, Chroman28, SSR240612, NPV-SAA164 and PS020990. The results of the docking study underline the role of specific receptor residues in ligand binding. The results of this study permitted to define a pharmacophore that describes the stereochemical requirements of antagonist binding, and can be used for the discovery of new compounds.
Collapse
Affiliation(s)
- Cecylia S Lupala
- Dept. of Chemical Engineering, Universitat Politecnica de Catalunya, ETSEIB. Av. Diagonal, 647, 08028 Barcelona, Spain
| | - Patricia Gomez-Gutierrez
- Dept. of Chemical Engineering, Universitat Politecnica de Catalunya, ETSEIB. Av. Diagonal, 647, 08028 Barcelona, Spain
| | - Juan J Perez
- Dept. of Chemical Engineering, Universitat Politecnica de Catalunya, ETSEIB. Av. Diagonal, 647, 08028 Barcelona, Spain.
| |
Collapse
|
3
|
Verma V, Sheikh Z, Ahmed AS. Nociception and role of immune system in pain. Acta Neurol Belg 2015; 115:213-20. [PMID: 25547878 DOI: 10.1007/s13760-014-0411-y] [Citation(s) in RCA: 36] [Impact Index Per Article: 4.0] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/30/2014] [Accepted: 12/14/2014] [Indexed: 01/13/2023]
Abstract
Both pain and inflammation are protective responses. However, these self-limiting conditions (with well-established negative feedback loops) become pathological if left uncontrolled. Both pain and inflammation can interact with each other in a multi-dimensional manner. These interactions are known to create an array of 'difficult to manage' pathologies. This review explains in detail the role of immune system and the related cells in peripheral sensitization and neurogenic inflammation. Various neuro-immune interactions are analyzed at peripheral, sensory and central nervous system levels. Innate immunity plays a critical role in central sensitization and in establishing acute pain as chronic condition. Moreover, inflammatory mediators also exhibit psychological effects, thus contributing towards the emotional elements associated with pain. However, there is also a considerable anti-inflammatory and analgesic role of immune system. This review also attempts to enlist various novel pharmacological approaches that exhibit their actions through modification of neuro-immune interface.
Collapse
Affiliation(s)
- Vivek Verma
- Division of Biomedical Sciences, Faculty of Dentistry, McGill University, Montreal, QC, Canada,
| | | | | |
Collapse
|
4
|
Aparaschivei R, Şunel V, Popa M, Desbrieres J. Sulfonic Derivatives of 2-Mercaptobenzoxazole and Its Conjugates with Poly(Maleic anhydride-alt-vinyl acetate) with Potential Pharmacological Applications. INT J POLYM MATER PO 2013. [DOI: 10.1080/00914037.2013.830254] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/09/2023]
|
5
|
Yanagisawa A, Yoshida K. Development of Asymmetric Reactions Catalyzed by Chiral Organotin-Alkoxide Reagents. CHEM REC 2013; 13:117-27. [DOI: 10.1002/tcr.201200019] [Citation(s) in RCA: 12] [Impact Index Per Article: 1.1] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/11/2012] [Indexed: 11/09/2022]
|
6
|
Harikrishnan PS, Rajesh SM, Perumal S, Almansour AI. A microwave-mediated catalyst- and solvent-free regioselective Biginelli reaction in the synthesis of highly functionalized novel tetrahydropyrimidines. Tetrahedron Lett 2013. [DOI: 10.1016/j.tetlet.2012.12.034] [Citation(s) in RCA: 34] [Impact Index Per Article: 3.1] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/29/2022]
|
7
|
Bryan MC, Biswas K, Peterkin TA, Rzasa RM, Arik L, Lehto SG, Sun H, Hsieh FY, Xu C, Fremeau RT, Allen JR. Chromenones as potent bradykinin B1 antagonists. Bioorg Med Chem Lett 2012; 22:619-22. [DOI: 10.1016/j.bmcl.2011.10.068] [Citation(s) in RCA: 8] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/01/2011] [Revised: 10/18/2011] [Accepted: 10/20/2011] [Indexed: 11/26/2022]
|
8
|
Discovery of dehydro-oxopiperazine acetamides as novel bradykinin B1 receptor antagonists with enhanced in vitro potency. Bioorg Med Chem Lett 2012; 22:1061-7. [DOI: 10.1016/j.bmcl.2011.11.112] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/24/2011] [Revised: 11/23/2011] [Accepted: 11/28/2011] [Indexed: 11/23/2022]
|
9
|
Fan W, Li W, Ma X, Tao X, Li X, Yao Y, Xie X, Zhang Z. Ru-Catalyzed Asymmetric Hydrogenation of γ-Heteroatom Substituted β-Keto Esters. J Org Chem 2011; 76:9444-51. [PMID: 21981465 DOI: 10.1021/jo201822k] [Citation(s) in RCA: 30] [Impact Index Per Article: 2.3] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/30/2022]
Affiliation(s)
- Weizheng Fan
- School of Chemistry
and Chemical
Engineering, Shanghai Jiao Tong University, 800 Dongchuan Road, Shanghai 200240, China
| | - Wanfang Li
- School of Chemistry
and Chemical
Engineering, Shanghai Jiao Tong University, 800 Dongchuan Road, Shanghai 200240, China
| | - Xin Ma
- School of Chemistry
and Chemical
Engineering, Shanghai Jiao Tong University, 800 Dongchuan Road, Shanghai 200240, China
| | - Xiaoming Tao
- School of Chemistry
and Chemical
Engineering, Shanghai Jiao Tong University, 800 Dongchuan Road, Shanghai 200240, China
| | - Xiaoming Li
- School of Chemistry
and Chemical
Engineering, Shanghai Jiao Tong University, 800 Dongchuan Road, Shanghai 200240, China
| | - Ying Yao
- School of Chemistry
and Chemical
Engineering, Shanghai Jiao Tong University, 800 Dongchuan Road, Shanghai 200240, China
| | - Xiaomin Xie
- School of Chemistry
and Chemical
Engineering, Shanghai Jiao Tong University, 800 Dongchuan Road, Shanghai 200240, China
| | - Zhaoguo Zhang
- School of Chemistry
and Chemical
Engineering, Shanghai Jiao Tong University, 800 Dongchuan Road, Shanghai 200240, China
- Shanghai Institute of Organic Chemistry, 345 Lingling Road, Shanghai 200032,
China
| |
Collapse
|
10
|
Biswas K, Peterkin TAN, Bryan MC, Arik L, Lehto SG, Sun H, Hsieh FY, Xu C, Fremeau RT, Allen JR. Discovery of Potent, Orally Bioavailable Phthalazinone Bradykinin B1 Receptor Antagonists. J Med Chem 2011; 54:7232-46. [DOI: 10.1021/jm200808v] [Citation(s) in RCA: 21] [Impact Index Per Article: 1.6] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/29/2022]
Affiliation(s)
- Kaustav Biswas
- Departments of †Chemistry Research and Discovery, ‡Pharmacokinetics and Drug Metabolism, and §Neuroscience Research, Amgen Inc., One Amgen Center Drive, Thousand Oaks, California 91320, United States
| | - Tanya A. N. Peterkin
- Departments of †Chemistry Research and Discovery, ‡Pharmacokinetics and Drug Metabolism, and §Neuroscience Research, Amgen Inc., One Amgen Center Drive, Thousand Oaks, California 91320, United States
| | - Marian C. Bryan
- Departments of †Chemistry Research and Discovery, ‡Pharmacokinetics and Drug Metabolism, and §Neuroscience Research, Amgen Inc., One Amgen Center Drive, Thousand Oaks, California 91320, United States
| | - Leyla Arik
- Departments of †Chemistry Research and Discovery, ‡Pharmacokinetics and Drug Metabolism, and §Neuroscience Research, Amgen Inc., One Amgen Center Drive, Thousand Oaks, California 91320, United States
| | - Sonya G. Lehto
- Departments of †Chemistry Research and Discovery, ‡Pharmacokinetics and Drug Metabolism, and §Neuroscience Research, Amgen Inc., One Amgen Center Drive, Thousand Oaks, California 91320, United States
| | - Hong Sun
- Departments of †Chemistry Research and Discovery, ‡Pharmacokinetics and Drug Metabolism, and §Neuroscience Research, Amgen Inc., One Amgen Center Drive, Thousand Oaks, California 91320, United States
| | - Feng-Yin Hsieh
- Departments of †Chemistry Research and Discovery, ‡Pharmacokinetics and Drug Metabolism, and §Neuroscience Research, Amgen Inc., One Amgen Center Drive, Thousand Oaks, California 91320, United States
| | - Cen Xu
- Departments of †Chemistry Research and Discovery, ‡Pharmacokinetics and Drug Metabolism, and §Neuroscience Research, Amgen Inc., One Amgen Center Drive, Thousand Oaks, California 91320, United States
| | - Robert T. Fremeau
- Departments of †Chemistry Research and Discovery, ‡Pharmacokinetics and Drug Metabolism, and §Neuroscience Research, Amgen Inc., One Amgen Center Drive, Thousand Oaks, California 91320, United States
| | - Jennifer R. Allen
- Departments of †Chemistry Research and Discovery, ‡Pharmacokinetics and Drug Metabolism, and §Neuroscience Research, Amgen Inc., One Amgen Center Drive, Thousand Oaks, California 91320, United States
| |
Collapse
|
11
|
3-Oxo-2-piperazinyl acetamides as potent bradykinin B1 receptor antagonists for the treatment of pain and inflammation. Bioorg Med Chem Lett 2011; 21:3384-9. [DOI: 10.1016/j.bmcl.2011.03.115] [Citation(s) in RCA: 7] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/05/2011] [Revised: 03/28/2011] [Accepted: 03/31/2011] [Indexed: 11/20/2022]
|
12
|
Yanagisawa A, Kushihara N, Yoshida K. Catalytic Enantioselective Synthesis of Chiral γ-Butyrolactones. Org Lett 2011; 13:1576-8. [DOI: 10.1021/ol200232w] [Citation(s) in RCA: 20] [Impact Index Per Article: 1.5] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/28/2022]
Affiliation(s)
- Akira Yanagisawa
- Department of Chemistry, Graduate School of Science, Chiba University, Chiba 263-8522, Japan
| | - Naoyuki Kushihara
- Department of Chemistry, Graduate School of Science, Chiba University, Chiba 263-8522, Japan
| | - Kazuhiro Yoshida
- Department of Chemistry, Graduate School of Science, Chiba University, Chiba 263-8522, Japan
| |
Collapse
|
13
|
Huang H, Player MR. Bradykinin B1 receptor antagonists as potential therapeutic agents for pain. J Med Chem 2010; 53:5383-99. [PMID: 20369879 DOI: 10.1021/jm1000776] [Citation(s) in RCA: 27] [Impact Index Per Article: 1.9] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/01/2023]
Affiliation(s)
- Hui Huang
- Johnson & Johnson Pharmaceutical Research and Development, Spring House, Pennsylvania 19477-0776, USA
| | | |
Collapse
|
14
|
Novel small molecule bradykinin B1 receptor antagonists. Part 3: Hydroxyurea derivatives. Bioorg Med Chem Lett 2010; 20:1233-6. [DOI: 10.1016/j.bmcl.2009.11.121] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/22/2009] [Revised: 11/23/2009] [Accepted: 11/24/2009] [Indexed: 11/24/2022]
|
15
|
Fincham CI, Bressan A, Paris M, Rossi C, Fattori D. Bradykinin receptor antagonists – a review of the patent literature 2005 – 2008. Expert Opin Ther Pat 2009; 19:919-41. [DOI: 10.1517/13543770902994389] [Citation(s) in RCA: 23] [Impact Index Per Article: 1.5] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/05/2022]
|
16
|
Sulfonamido-aryl ethers as bradykinin B1 receptor antagonists. Bioorg Med Chem Lett 2009; 19:119-22. [DOI: 10.1016/j.bmcl.2008.11.005] [Citation(s) in RCA: 8] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/09/2008] [Revised: 10/28/2008] [Accepted: 11/03/2008] [Indexed: 11/21/2022]
|